Nichola Cooper
Imperial College London
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nichola Cooper as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:45 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04581954 · Inflammatory Signal Inhibitors for COVID-19 (MATIS)Imperial College London · completed · Coronavirus, Covid19, Pneumonia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:45 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- 2,512 citationsRCR 79.3
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.N Engl J Med · 2021800 citationsRCR 45.9
- 330 citationsRCR 8.2
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.Am J Hematol · 2018309 citationsRCR 12.1
- 248 citationsRCR 5.9
- Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial.J Am Diet Assoc · 1995201 citationsRCR 7.3
- 160 citationsRCR 5.1
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.N Engl J Med · 2022134 citationsRCR 10.9
- A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment.J Pain · 2010113 citationsRCR 4.7
- 111 citationsRCR 5.3